Insights into the structure of class B GPCRs
By tailoring each dose adjustment to the patient's specific progress and side effects, the guiding principle is to find the lowest effective dose that comfortably sustains long-term results, rather than rushing to the maximum dose in the shortest time possible
On average, they suffered from type 2 diabetes for 12 years, but this varied greatly among participants
Tirzepatide is a dual GLP-1/GIP agonist, already FDA- and EMA-approved for type 2 diabetes (Mounjaro) and obesity (Zepbound)
Functional MRI trials consistently demonstrate reduced activation in mesolimbic and cortical reward circuits following treatment, reflecting diminished hedonic drive and a lower motivational response to high-calorie food cues (180, 181)
GLP-1s also act on the central nervous system, particularly the brainstem and hypothalamus, where it regulates satiety and appetite